Durvalumab for treating limited-stage small-cell lung cancer after chemoradiation: a single technology appraisal
Durvalumab for treating limited-stage small-cell lung cancer after chemoradiation: a single technology appraisal
This report is a critique of the company’s submission (CS) to the National Institute for Health and Care Excellence (NICE) from AstraZeneca on the clinical effectiveness and cost effectiveness of durvalumab for treating limited-stage small-cell lung cancer (LS-SCLC) after chemoradiation (CRT). It identifies the strengths and weakness of the CS.
Southampton Health Technology Assessments Centre
Pickett, Karen
1bac9d88-da29-4a3e-9fd2-e469f129f963
Takahashi, Marcia
fa084efd-dc46-4325-8fc9-d3f6d1f8b5d0
Kalita, Neelam
da42f168-a3cc-44c9-bafb-2801ff57914b
Shepherd, Jonathan
dfbca97a-9307-4eee-bdf7-e27bcb02bc67
2025
Pickett, Karen
1bac9d88-da29-4a3e-9fd2-e469f129f963
Takahashi, Marcia
fa084efd-dc46-4325-8fc9-d3f6d1f8b5d0
Kalita, Neelam
da42f168-a3cc-44c9-bafb-2801ff57914b
Shepherd, Jonathan
dfbca97a-9307-4eee-bdf7-e27bcb02bc67
Pickett, Karen, Takahashi, Marcia, Kalita, Neelam and Shepherd, Jonathan
(2025)
Durvalumab for treating limited-stage small-cell lung cancer after chemoradiation: a single technology appraisal
Southampton Health Technology Assessments Centre
123pp.
Record type:
Monograph
(Project Report)
Abstract
This report is a critique of the company’s submission (CS) to the National Institute for Health and Care Excellence (NICE) from AstraZeneca on the clinical effectiveness and cost effectiveness of durvalumab for treating limited-stage small-cell lung cancer (LS-SCLC) after chemoradiation (CRT). It identifies the strengths and weakness of the CS.
Text
Durvalumab EAG report
- Other
More information
Published date: 2025
Identifiers
Local EPrints ID: 506635
URI: http://eprints.soton.ac.uk/id/eprint/506635
PURE UUID: d086beb9-6fac-4bfc-9f64-3eae8efe7518
Catalogue record
Date deposited: 12 Nov 2025 17:46
Last modified: 13 Nov 2025 03:00
Export record
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics